An interventional study of Homologous Recombination Deficiency (HRD) and ALK/ROS1/MET in Advanced Solid Tumors, Metastatic Solid Tumors and Locally Advanced Solid Tumors, sponsored by National Cancer Center, Korea. Active, not recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by National Cancer Center, Korea · Not applicable, Interventional, and Screening
Study Overview This study evaluates a proteogenomic screening platform to identify precise therapeutic targets for patients with advanced solid tumors. While traditional precision medicine relies on DNA sequencing (genomics), this research adds protein analysis (proteomics) to better understand how cancer cells function and respond to treatment.
Background and Purpose Standard genomic testing often fails to predict whether a patient will respond to a specific drug because DNA mutations do not always result in active protein expression. By integrating Whole Exome Sequencing (WES) with phosphoproteomics (the study of protein activation), this study aims to:
Target Population
Study Procedures
Potential Benefits and Risks
National Cancer Center, Korea is the lead sponsor of 203 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
HRD-targeted therapy (for Homologous Recombination Deficiency-positive signatures) (Nesuparib, Cisplatin)
Drug: Homologous Recombination Deficiency (HRD)
ubjects with specific ALK, ROS1, or MET gene variants or protein overexpression identified through proteogenomic analysis
Drug: ALK/ROS1/MET
Routine oncological treatments administered according to institutional guidelines for patients whose proteogenomic profile does not match a specific study sub-protocol
Drug: standard care treatment
This arm consists of subjects identified with Homologous Recombination Deficiency (HRD)-positive proteogenomic signatures through the master screening protocol . These subjects are eligible for matching targeted therapy sub-protocols
ALK/ROS1/MET-targeted therapy (Crizotinib 250mg )
This arm is for subjects who do not meet the specific molecular criteria for the available targeted sub-protocols following proteogenomic screening . These subjects will continue to receive the standard-of-care treatment at their respective institutions
Rate of Successful Identification of Actionable Therapeutic Targets
The percentage of subjects whose proteogenomic profiles-characterized through integrated Whole Exome Sequencing (WES) and phosphoproteomic analysis of fresh-frozen (FF) specimens-allow for the identification of actionable therapeutic targets for enrollment in specific basket trial sub-protocols (e.g., HRD or ALK/ROS1/MET)
Time frame: From the date of pre-treatment tissue sample collection until the completion of proteogenomic analysis and report generation, assessed up to 3 weeks (21 days) per participant.
Logistical Success Rate of Fresh-Frozen (FF) Specimen Transport
The proportion of collected specimens that successfully meet the strict Cold Ischemia Time (CIT) requirements (the interval from extraction to freezing) as part of the established nationwide delivery and logistics system
Time frame: From the time of tissue collection at participating hospitals until receipt and quality control verification at the central biobank, assessed up to 14 days per specimen.
Progression-Free Survival (PFS) and Overall Survival (OS)
Evaluation of survival outcomes relative to the identified proteogenomic profiles and subsequent treatment assignments using Kaplan-Meier estimates and Cox-proportional hazards regression
Time frame: From enrollment until disease progression or death from any cause, whichever occurs first, assessed up to 5 years.
Frequency and Distribution of Molecular Signature
Descriptive characterization of the frequency of targetable molecular variants and proteogenomic signatures across various advanced solid tumor types
Time frame: From enrollment through completion of molecular signature profiling for all participants, assessed up to 36 months.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kenny-Caffey syndrome, Type 1
National Cancer Center, Korea →